Filing Flows › Cue Biopharma (CUE) › Q2 2025
Cue Biopharma (CUE) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Cue Biopharma (CUE) reported revenue of $3.0M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +602% from the quarter before. Operating margin was -292.3%, net loss $8.5M (287.1% of revenue).
Cue Biopharma, Q2 2025: revenue $3.0M (+11% year over year), operating margin -292.3%, net loss $8.5M, operating cash flow −$3.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | +602% | +11% |
| Operating profit | −$8.6M | — | — |
| Net earnings | −$8.5M | — | — |
| Operating cash flow | −$3.4M | — | — |
What changed
Revenue was $3.0M in Q2 2025, up 11% year over year and up 602% from the previous quarter.
Operating costs exceeded revenue by $8.6M, an operating margin of -292.3%. Total costs fell 11% while revenue rose 11%. The quarter ended with a net loss of $8.5M, narrower than the previous quarter's $12.3M loss.
Operating cash flow was −$3.4M. Non-cash charges added back $99K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $27K exceeded it, leaving free cash flow of −$3.4M.
Questions
What was Cue Biopharma's revenue in the second quarter 2025?
Cue Biopharma (CUE) reported revenue of $3.0M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +602% from the quarter before.
Was Cue Biopharma profitable in the second quarter 2025?
Operating loss was $8.6M (-292.3% of revenue) and net loss $8.5M.
Source: Cue Biopharma 10-Q on SEC EDGAR.